- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05389007
.German TTP-Registry (Thrombotic Thrombocytopenic Purpura) (RGTTP)
May 20, 2022 updated by: Charis v. Auer, Johannes Gutenberg University Mainz
German TTP- Registry- Prospective Cohort of Patients With Acquired Thrombotic Thrombocytopenic Purpura (aTTP): Pathophysiology, Diagnosis, Treatment and Follow-Up
Open, multi-center, observational, prospective cohort study, only disease-indicated treatment, in patients with clinically diagnosed acquired and congenital TTP regardless of gender, ethnicity, and comorbidities, over the age of 18 for 1.) prospective investigation of patients with TTP in an acute bout and during long-term follow and 2.) assessment of prevalence, course of disease, success of therapy, possible triggers for relapses and possibilities for better diagnosis and prognosis.
Study Overview
Status
Recruiting
Conditions
Detailed Description
1.) Identification of predictive markers for morbidity and mortality in acute TTP and in TTP relapses using a prospective long-term registry and 2.) Investigation of the pathophysiological processes in acute bouts and in remission by recording the clinical symptoms and diagnostics for a better understanding of the course of the disease, optimization of diagnostic procedures and their correlation with the clinical course, recording of therapy response of all therapeutic options in acute bouts, observation of current treatment options to evaluate outcome and prognostic markers and recording of clinical and laboratory chemical data during follow-up to assess long-term morbidity.
Study Type
Observational
Enrollment
156
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Charis v. Auer-Wegener
- Email: charis.von-auer@unimedizin-mainz.de
Study Locations
-
-
-
Mainz, Germany, 55131
- Recruiting
- University Hospital Mainz, Hematology
-
Contact:
- Charis v. Auer-Wegener
- Email: charis.von-auer@unimedizin-mainz.de
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Sampling Method
Non-Probability Sample
Study Population
It is planned to include all patients with TTP in Germany.
Description
Inclusion Criteria:
- Patients with clinically diagnosed acquired and congenital TTP regardless of gender, ethnicity, and comorbidities, over the age of 18.
- Patients incapable to give consent, who are accompanied by a legal representative during admission to the study, after the written informed consent of the legal representative.
- Written informed consent of the patient.
Exclusion Criteria:
- Patients who are not able to understand the German or English language.
- Patients who are permanently unable to communicate and who are not accompanied by a legal representative.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Prospective
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Predictive markers for morbidity and mortality
Time Frame: 3 years
|
Identification of predictive markers for morbidity and mortality in acute TTP and in TTP relapses using a prospective long-term registry
|
3 years
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Investigators
- Principal Investigator: Charis v. Auer-Wegener, Universitätsmedizin Mainz
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
July 8, 2016
Primary Completion (Anticipated)
July 1, 2025
Study Registration Dates
First Submitted
May 9, 2022
First Submitted That Met QC Criteria
May 20, 2022
First Posted (Actual)
May 24, 2022
Study Record Updates
Last Update Posted (Actual)
May 24, 2022
Last Update Submitted That Met QC Criteria
May 20, 2022
Last Verified
May 1, 2022
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- RGTTP
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
No
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Thrombotic Thrombocytopenic Purpura
-
Insel Gruppe AG, University Hospital BernSwiss National Science Foundation; Mach Gaensslen Foundation; Baxalta Innovations...RecruitingThrombotic Thrombocytopenic Purpura | Congenital Thrombotic Thrombocytopenic Purpura | Familial Thrombotic Thrombocytopenic Purpura | Thrombotic Thrombocytopenic Purpura, Congenital | Upshaw-Schulman SyndromeUnited States, Austria, Czechia, Germany, Japan, Norway, Switzerland
-
ShireTakeda Development Center Americas, Inc.CompletedAcquired Thrombotic Thrombocytopenic Purpura (aTTP)United States, Spain, Canada, United Kingdom, France, Germany, Italy
-
TakedaShire; Takeda Development Center Americas, Inc.RecruitingThrombotic Thrombocytopenic Purpura (TTP)China, United States, France, Japan, Poland, Germany, Austria, Spain, Italy, Switzerland, United Kingdom
-
Turkish Hematology AssociationSanofiRecruitingTTP - Thrombotic Thrombocytopenic PurpuraTurkey
-
University of CologneRecruitingAcquired Thrombotic Thrombocytopenic PurpuraGermany
-
Peking Union Medical College HospitalNot yet recruitingThrombotic Thrombocytopenic Purpura, AcquiredChina
-
Fundación Española de Hematología y HemoterapíaRecruitingAcquired Thrombotic Thrombocytopenic PurpuraSpain, Portugal
-
University of CologneRecruitingAcquired Thrombotic Thrombocytopenic PurpuraGermany
-
TakedaAvailableThrombotic Thrombocytopenic Purpura (TTP)
-
Ablynx, a Sanofi companyCompletedAcquired Thrombotic Thrombocytopenic PurpuraUnited States, Austria, Belgium, France, Germany, Israel, Italy, Spain, Switzerland, United Kingdom, Bulgaria, Romania, Australia